Key result
Aspirin reduced platelet COX-1-derived enzymatically oxygenated phospholipids while elevating diacyl 12-LOX-derived species in males, and P2Y12 inhibition reduced 12-LOX-derived species in leukocytes.
Why the study?
Enzymatically oxygenated phospholipids are pro-coagulant in model systems, but their generation in arterial thrombotic disease and modulation by common therapies is unknown.
Do common anti-platelet therapies (aspirin, P2Y12 inhibitors) modulate procoagulant enzymatically oxygenated phospholipids in arterial disease?
Cohort (n=118)
Yes
Do common anti-platelet therapies (aspirin, P2Y12 inhibitors) modulate procoagulant enzymatically oxygenated phospholipids in arterial disease?
Common anti-platelet therapies like aspirin and P2Y12 inhibitors significantly alter the generation of pro-coagulant enzymatically oxygenated phospholipids, highlighting a novel mechanism that may influence thrombotic risk.
Answers are grounded in this paper and cite their sources.
First eoxPL characterization in arterial disease cohorts is hypothesis-generating; prospective studies needed before any clinical role.
Enzymatically oxygenated phospholipids (eoxPL) formed by lipoxygenases (LOX) and cyclooxygenase (COX) in platelets and leukocytes are pro-coagulant in multiple model systems. However, their generation in arterial thrombotic disease, and how their levels are modulated by common therapies is unknown. Here, eoxPL were first characterized in isolated platelets and leukocytes from an arterial vascular disease cohort, a healthy cohort administered low dose aspirin, and from retrieved human arterial thrombi. In both cohorts, aspirin reduced platelet COX-1-derived eoxPL, while elevating diacyl 12-LOX-derived eoxPL in males, through enhanced Lands’ cycle esterification. Conversely, P2Y12 inhibition reduced 12-LOX-derived eoxPL in leukocytes. Complex aspirin-dependent gender and seasonal effects on platelet eoxPL were seen in healthy subjects. Limb or coronary (STEMI) thrombi showed a platelet eoxPL signature while carotid thrombi had a white cell profile. Mice genetically lacking leukocyte 12/15-LOX, which are deficient in eoxPL, generated smaller carotid thrombi in vivo. In summary, pro-coagulant eoxPL generation is altered in human arterial vascular disease by commonly used cardiovascular therapies. These changes to the phospholipid composition of blood cells in humans at risk of thrombotic events may be clinically significant where the pro-coagulant membrane plays a central but poorly understood role in driving elevated thrombotic risk. Key Points eoxPL generation is altered in health and arterial vascular disease by aspirin or P2Y12 inhibitors, and shows gender and seasonal variation. Aspirin regulates eoxPL by inhibiting cyclooxygenase and modulating Lands’ cycle. The eoxPL profile of human arterial thrombi identifies platelet and leukocyte involvement. Mice deficient in LOX-derived eoxPL form smaller arterial thrombi in vivo .
No takes yet. Share an insight, caveat, or question.
Protty et al. (2022) conducted a cohort in Arterial vascular disease (n=118). Aspirin and P2Y12 inhibitors vs. Healthy controls or pre-treatment baseline was evaluated on Levels of enzymatically oxygenated phospholipids (eoxPL). Aspirin reduced platelet COX-1-derived enzymatically oxygenated phospholipids while elevating diacyl 12-LOX-derived species in males, and P2Y12 inhibition reduced 12-LOX-derived species in leukocytes.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: